MX389847B - Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. - Google Patents
Composiciones de ésteres de ácido cannabidiólico y usos de las mismas.Info
- Publication number
- MX389847B MX389847B MX2019015311A MX2019015311A MX389847B MX 389847 B MX389847 B MX 389847B MX 2019015311 A MX2019015311 A MX 2019015311A MX 2019015311 A MX2019015311 A MX 2019015311A MX 389847 B MX389847 B MX 389847B
- Authority
- MX
- Mexico
- Prior art keywords
- compositions
- acid esters
- cannabidiolic acid
- cannabidiolic
- symptoms
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/76—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring
- C07C69/94—Esters of carboxylic acids having a carboxyl group bound to a carbon atom of a six-membered aromatic ring of polycyclic hydroxy carboxylic acids, the hydroxy groups and the carboxyl groups of which are bound to carbon atoms of six-membered aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/12—Acetic acid esters
- C07C69/16—Acetic acid esters of dihydroxylic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C69/00—Esters of carboxylic acids; Esters of carbonic or haloformic acids
- C07C69/02—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen
- C07C69/22—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety
- C07C69/28—Esters of acyclic saturated monocarboxylic acids having the carboxyl group bound to an acyclic carbon atom or to hydrogen having three or more carbon atoms in the acid moiety esterified with dihydroxylic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Hospice & Palliative Care (AREA)
- Otolaryngology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Epidemiology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762522243P | 2017-06-20 | 2017-06-20 | |
| PCT/IL2018/050678 WO2018235079A1 (en) | 2017-06-20 | 2018-06-20 | CANNABIDIOLIC ACID ESTER COMPOSITIONS AND USES THEREOF |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2019015311A MX2019015311A (es) | 2022-02-02 |
| MX389847B true MX389847B (es) | 2025-03-20 |
Family
ID=62875079
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019015311A MX389847B (es) | 2017-06-20 | 2018-06-20 | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US11440870B2 (https=) |
| EP (1) | EP3509638B1 (https=) |
| JP (1) | JP2020524679A (https=) |
| CN (2) | CN121534035A (https=) |
| AU (1) | AU2018287018B2 (https=) |
| BR (1) | BR112019026916A2 (https=) |
| CA (1) | CA3067512A1 (https=) |
| DK (1) | DK3509638T3 (https=) |
| ES (1) | ES2909350T3 (https=) |
| MX (1) | MX389847B (https=) |
| PT (1) | PT3509638T (https=) |
| WO (1) | WO2018235079A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10239808B1 (en) | 2016-12-07 | 2019-03-26 | Canopy Holdings, LLC | Cannabis extracts |
| PT3509638T (pt) | 2017-06-20 | 2022-03-02 | Univ Guelph | Composições de ésteres de ácido canabidiólico e suas utilizações |
| EP3745884A1 (en) | 2018-01-31 | 2020-12-09 | Canopy Holdings, Llc | Hemp powder |
| CA3119729A1 (en) | 2018-10-10 | 2020-04-16 | Treehouse Biotech, Inc. | Synthesis of cannabigerol |
| US20220054380A1 (en) * | 2018-12-25 | 2022-02-24 | Epm (Ip), Inc. | Cannabidioloic acid esters for cosmetic or edible compositions |
| KR20210151816A (ko) * | 2019-03-12 | 2021-12-14 | 이피엠 (아이피), 인코포레이티드 | 칸나비노이드 산 에스테르 조성물 및 이의 용도 |
| JP2022545491A (ja) | 2019-08-22 | 2022-10-27 | イーピーエム（アイピー）， インコーポレイテッド | カンナビノイド酸エステル組成物およびその使用 |
| WO2021137224A1 (en) * | 2020-01-01 | 2021-07-08 | Epm Group, Inc. | Cannabidiolic acid esters for treating muscular dystrophy |
| IL275108A (en) * | 2020-06-03 | 2022-01-01 | Epm Ip Inc | Abnormal acid cannabidiol (abn-cbd) derivatives and their uses |
| US11672761B2 (en) | 2020-11-16 | 2023-06-13 | Orcosa Inc. | Rapidly infusing platform and compositions for therapeutic treatment in humans |
| WO2022103638A1 (en) | 2020-11-16 | 2022-05-19 | Orcosa Inc. | Cannabinoids in the treatment of autism spectrum disorder |
| IL303739A (en) * | 2020-12-24 | 2023-08-01 | Buzzelet Development And Technologies Ltd | Compositions including cannabinoid esters |
| US20230066947A1 (en) * | 2021-08-04 | 2023-03-02 | Max Hammond | Method for the augmentation of substance abuse therapies using cannabinoid formulations |
Family Cites Families (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2318468A1 (fr) * | 1975-07-17 | 1977-02-11 | Jaeger | Dispositif electronique d'enregistrement et de lecture de donnees concernant differents parametres au cours d'un cycle predetermine, fonction de l'un desdits parametres |
| US5342971A (en) | 1992-12-29 | 1994-08-30 | The Australian National University | Process for the preparation of dibenzo[b,d]pyrans |
| WO1999057107A2 (en) | 1998-05-04 | 1999-11-11 | The University Of Connecticut | Cannabinoids selective for the cb2 receptor |
| IL136839A (en) | 2000-06-16 | 2006-12-10 | Yissum Res Dev Co | Pharmaceutical compositions comprising cannabidiol derivatives, and processes for the preparation of same |
| US20050287180A1 (en) | 2004-06-15 | 2005-12-29 | Chen Andrew X | Phospholipid compositions and methods for their preparation and use |
| CN102766128A (zh) | 2005-09-29 | 2012-11-07 | 阿尔巴尼分子研究公司 | δ-9-四氢大麻酚的生成方法 |
| CN101384012B (zh) * | 2008-10-22 | 2012-05-23 | 华为终端有限公司 | 系统端和终端的交互媒体文档更新方法及装置 |
| DE102009019322A1 (de) * | 2009-04-30 | 2010-11-11 | The Health Concept Gmbh | Verfahren zur Herstellung von Synthetischen Cannabinoiden |
| GB2478595B (en) | 2010-03-12 | 2018-04-04 | Gw Pharma Ltd | Phytocannabinoids in the treatment of glioma |
| GB2494461A (en) | 2011-09-12 | 2013-03-13 | Gw Pharma Ltd | Phytocannabinoids for use in the treatment of invasive cancers or metastases |
| GB2515312A (en) | 2013-06-19 | 2014-12-24 | Gw Pharma Ltd | The use of phytocannabinoids in the treatment of ovarian carcinoma |
| EP2842933B1 (de) * | 2013-09-03 | 2015-07-29 | Symrise AG | Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung |
| EP3131874B1 (en) * | 2014-04-16 | 2018-07-25 | Emerald Health Pharmaceuticals Inc. | Novel cannabidiol quinone derivatives |
| GB2527590A (en) | 2014-06-27 | 2015-12-30 | Otsuka Pharma Co Ltd | Active pharmaceutical ingredient (API) comprising cannabinoids for use in the treatment of cancer |
| GB2531283A (en) | 2014-10-14 | 2016-04-20 | Gw Pharma Ltd | Use of cannabidiols in the treatment of degenerative skeletal muscle diseases |
| EP3061450A1 (de) | 2015-02-26 | 2016-08-31 | Symrise AG | Mischungen cannabinoider Verbindungen, deren Herstellung und Verwendung |
| GB2551987A (en) | 2016-07-01 | 2018-01-10 | Gw Res Ltd | Oral cannabinoid formulations |
| CN106810426B (zh) | 2016-12-29 | 2020-05-08 | 暨明医药科技（苏州）有限公司 | 一种大麻二酚的合成方法 |
| PT3509638T (pt) | 2017-06-20 | 2022-03-02 | Univ Guelph | Composições de ésteres de ácido canabidiólico e suas utilizações |
| WO2019234728A1 (en) | 2018-06-04 | 2019-12-12 | Al&Am Pharmachem Ltd. | Cannabinolic acid derivatives and uses thereof |
-
2018
- 2018-06-20 PT PT187399589T patent/PT3509638T/pt unknown
- 2018-06-20 ES ES18739958T patent/ES2909350T3/es active Active
- 2018-06-20 BR BR112019026916-9A patent/BR112019026916A2/pt not_active Application Discontinuation
- 2018-06-20 WO PCT/IL2018/050678 patent/WO2018235079A1/en not_active Ceased
- 2018-06-20 DK DK18739958.9T patent/DK3509638T3/da active
- 2018-06-20 CN CN202511437638.6A patent/CN121534035A/zh active Pending
- 2018-06-20 CA CA3067512A patent/CA3067512A1/en active Pending
- 2018-06-20 JP JP2019570108A patent/JP2020524679A/ja active Pending
- 2018-06-20 CN CN201880041597.0A patent/CN111032088A/zh active Pending
- 2018-06-20 AU AU2018287018A patent/AU2018287018B2/en active Active
- 2018-06-20 US US16/343,050 patent/US11440870B2/en active Active
- 2018-06-20 MX MX2019015311A patent/MX389847B/es unknown
- 2018-06-20 EP EP18739958.9A patent/EP3509638B1/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| US11440870B2 (en) | 2022-09-13 |
| JP2020524679A (ja) | 2020-08-20 |
| AU2018287018B2 (en) | 2022-04-28 |
| US20200115317A1 (en) | 2020-04-16 |
| CN121534035A (zh) | 2026-02-17 |
| MX2019015311A (es) | 2022-02-02 |
| CN111032088A (zh) | 2020-04-17 |
| BR112019026916A2 (pt) | 2020-06-30 |
| DK3509638T3 (da) | 2022-04-11 |
| AU2018287018A1 (en) | 2020-01-30 |
| CA3067512A1 (en) | 2018-12-27 |
| WO2018235079A1 (en) | 2018-12-27 |
| EP3509638A1 (en) | 2019-07-17 |
| EP3509638B1 (en) | 2022-01-12 |
| PT3509638T (pt) | 2022-03-02 |
| ES2909350T3 (es) | 2022-05-06 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX389847B (es) | Composiciones de ésteres de ácido cannabidiólico y usos de las mismas. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| CL2017002123A1 (es) | Heterociclos biciclicos como inhibidores de fgnr | |
| CO2017013443A2 (es) | Composiciones que comprenden cepas bacterianas del género blautia | |
| MX385845B (es) | Usos y composiciones de la flagelina | |
| DOP2016000109A (es) | Formas sólidas de ácido {[5-(3-clorofenil) -3-hidroxipiridin-2-carbonil] amino} acético, composiciones, y usos de las mismas. | |
| BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
| NI201600071A (es) | Compuestos de inhibidor de autotaxina | |
| MX2017011269A (es) | Inhibidores de lisil oxidasa tipo 2 fluorinados y usos de los mismos. | |
| BR112017017727A8 (pt) | Heterociclos bicíclicos como inibidores de fgfr4 | |
| UY34617A (es) | Composiciones veterinarias orales parasiticidas que comprenden agentes activos de acción sistémica, métodos y usos de las mismas | |
| MX377340B (es) | Composiciones en solución sólida y uso en el tratamiento de enfermedades cardiovasculares. | |
| MX373129B (es) | Derivados de indolizina como inhibidores de fosfoinositido-3 cinasas. | |
| CL2017001301A1 (es) | Composiciones oftálmicas estabilizadas de omega 3 | |
| MX395231B (es) | Compuestos eficaces en el tratamiento de la hepatotoxicidad y enfermedades de hígado graso, y uso de los mismos. | |
| MX370900B (es) | Derivados del isocromeno como inhibidores de las fosfoinositido-3 cinasas. | |
| UY36171A (es) | Derivados heteroaromáticos bicíclicos fusionados como inhibidores de quinasa | |
| MX2018007390A (es) | Composiciones que comprenden acido 15-hidroxi eicosapentaenoico (15-hepe) y metodos de uso del mismo. | |
| DOP2016000170A (es) | Compuestos derivados de hidroxiformamida y usos del mismo | |
| NI201600070A (es) | Inhibidores tetracíclicos de autotaxina | |
| MX2016012784A (es) | Composiciones farmaceuticas solidas que comprenden derivados de biopterina y usos de tales composiciones. | |
| MX2017013137A (es) | Derivados de cromeno como inhibidores de las fosfoinositido-3-cina sas. | |
| MX391757B (es) | Formulaciones de ácido 1-amino-1-ciclopropanocarboxílico. | |
| BR112017001971A2 (pt) | ?métodos e composições para diagnosticar e tratar distúrbios inflamatórios intestinais? | |
| MX2017014456A (es) | Usos terapeuticos de l-4-cloroquinurenina. |